Search

Author/Creator Moore, Gregory

1. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one. Issue 1 (November 2016)

Authors:
Lundqvist, Andreas; van Hoef, Vincent; Zhang, Xiaonan; Wennerberg, Erik; Lorent, Julie; Witt, Kristina; Sanz, Laia; Liang, Shuo; Murray, Shannon; Larsson, Ola; Kiessling, Rolf; Mao, Yumeng; Sidhom, John-William; Bessell, Catherine; Havel, Jonathan; Schneck, Jonathan; Chan, Timothy; Sachsenmeier, ...
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 4:Issue 1(2016)
Page Start:
1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one. Issue 1 (November 2016)

Authors:
Lundqvist, Andreas; van Hoef, Vincent; Zhang, Xiaonan; Wennerberg, Erik; Lorent, Julie; Witt, Kristina; Sanz, Laia; Liang, Shuo; Murray, Shannon; Larsson, Ola; Kiessling, Rolf; Mao, Yumeng; Sidhom, John-William; Bessell, Catherine; Havel, Jonathan; Schneck, Jonathan; Chan, Timothy; Sachsenmeier, ...
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 4:Issue 1(2016)
Page Start:
1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. 697 Tumor-targeted CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors. (9th November 2020)

Authors:
Hedvat, Michael; Zeng, Veronica; Diaz, Juan; Bonzon, Christine; Avery, Kendra; Rashid, Rumana; Leung, Irene; Bartlow, Norm; Bakhit, Charles; Dragovich, Matthew; Bogart, Liz; Muchhal, Umesh; Desjarlais, John; Moore, Gregory
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 3
Page Start:
A419
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. 697 Tumor-targeted CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors. (9th November 2020)

Authors:
Hedvat, Michael; Zeng, Veronica; Diaz, Juan; Bonzon, Christine; Avery, Kendra; Rashid, Rumana; Leung, Irene; Bartlow, Norm; Bakhit, Charles; Dragovich, Matthew; Bogart, Liz; Muchhal, Umesh; Desjarlais, John; Moore, Gregory
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 3
Page Start:
A739
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. 714 PD1 x TGFβR2 bispecifics selectively block TGFβR2 on PD1-positive T cells, promote T cell activation, and elicit an anti-tumor response in solid tumors. (9th November 2020)

Authors:
Moore, Gregory; Schubbert, Suzanne; Bonzon, Christine; Avery, Kendra; Rashid, Rumana; Pong, Erik; Ochyl, Lukasz; Nisthal, Alex; Chu, Seung; Ernst, James; Desjarlais, John
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 3
Page Start:
A756
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. 714 PD1 x TGFβR2 bispecifics selectively block TGFβR2 on PD1-positive T cells, promote T cell activation, and elicit an anti-tumor response in solid tumors. (9th November 2020)

Authors:
Moore, Gregory; Schubbert, Suzanne; Bonzon, Christine; Avery, Kendra; Rashid, Rumana; Pong, Erik; Ochyl, Lukasz; Nisthal, Alex; Chu, Seung; Ernst, James; Desjarlais, John
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 3
Page Start:
A428
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. 718 AMG 509, a STEAP1 x CD3 bispecific XmAb® 2+1 immune therapy, exhibits avidity-driven binding and preferential killing of high STEAP1-expressing prostate and Ewing sarcoma cancer cells. (9th November 2020)

Authors:
Li, Cong; Fort, Madeline; Liang, Lingming; Moore, Gregory; Bernett, Matthew; Muchhal, Umesh; Osgood, Tao; Yabut, Rodolfo; Kaliyaperumal, Sarav; Harrold, John; Canon, Jude; Rogojina, Anna; Kurmasheva, Raushan; Desjarlais, John; Houghton, Peter; Nolan-Stevaux, Olivier
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 3
Page Start:
A430
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. 718 AMG 509, a STEAP1 x CD3 bispecific XmAb® 2+1 immune therapy, exhibits avidity-driven binding and preferential killing of high STEAP1-expressing prostate and Ewing sarcoma cancer cells. (9th November 2020)

Authors:
Li, Cong; Fort, Madeline; Liang, Lingming; Moore, Gregory; Bernett, Matthew; Muchhal, Umesh; Osgood, Tao; Yabut, Rodolfo; Kaliyaperumal, Sarav; Harrold, John; Canon, Jude; Rogojina, Anna; Kurmasheva, Raushan; Desjarlais, John; Houghton, Peter; Nolan-Stevaux, Olivier
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 3
Page Start:
A760
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗